Real World Outcomes with Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody: A Single Center Experience for Relapsed/ Refractory Multiple Myeloma (RRMM)

被引：0

作者：

Gill, Sarvarinder Kaur ^{[1
]}

Fleming, Erika ^{[2
]}

Gebre, Helen ^{[1
]}

Bangolo, Ayrton, I ^{[3
]}

Siegel, David S. ^{[4
,5
]}

Vesole, David H. ^{[6
]}

Biran, Noa ^{[6
]}

Parmar, Harsh ^{[6
]}

Phull, Pooja ^{[6
]}

机构：

[1] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Hackensack Meridian Sch Med, Nutley, NJ USA

[3] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Edgewater, NJ USA

[4] Hackensack Meridian Hlth, John Theurer Canc Ctr, Div Multiple Myeloma, Hackensack, NJ USA

[5] Ctr Discovery & Innovat, Hackensack, NJ USA

[6] Hackensack Univ Med Ctr, Div Multiple Myeloma, John Theurer Canc Ctr, Hackensack, NJ USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-210350

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7047 / 7048

页数：2

共 50 条

[31] First Results From the RedirecTT-1 Study With Teclistamab (Tec) plus Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Cohen, Yael
Morillo, Daniel
Gatt, Moshe
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Oriol, Albert
Ocio, Enrique
Yoon, Sung-Soo
Mateos, Maria-Victoria
Chu, Michael
Rodriguez-Otero, Paula
Chu, Michael
Rodriguez-Otero, Paula
Avivi, Irit
Guo, Yue
Krevvata, Maria
Peterson, Michelle
Beelen, Melissa
Vanak, Jill
Banerjee, Arnob
Magen, Hila
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S478 - S479
[32] Real-World Experience With Talquetamab Clinical Management in Relapsed Refractory Multiple Myeloma (RRMM): A Qualitative Study of US Healthcare Providers
Schinke, Carolina
Dhakal, Binod
Mazzoni, Sandra
Shenoy, Samantha
Scott, Sara
Richards, Tiffany
Le, Hoa
DeBrosse, Amalia
Okorozo, Peter
McDowell, Rachel
Patel, Saurabh
Bunn, Jonathan
Hawks, Kelly
Zhang, Xinke
Rodriguez-Valdes, Cesar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S265 - S266
[33] Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1+1 greater than 2?
Li, Chenggong
Mei, Heng
LANCET HAEMATOLOGY, 2024, 11 (10): : e712 - e713
[34] BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy
Joiner, Laura
Costa, Luciano
Giri, Smith
Ravi, Gayathri
Godby, Kelly
Hagedorn, Caitlin
Bal, Susan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S61 - S62
[35] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Cohen, Yael C.
Morillo, Daniel
Gatt, Moshe E.
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Oriol, Albert
Ocio, Enrique M.
Yoon, Sung-Soo
Mateos, Maria-Victoria
Chu, Michael
Rodriguez-Otero, Paula
Avivi, Irit
Guo, Yue
Krevvata, Maria
Peterson, Michelle R.
Beelen, Melissa Jo
Vanak, Jill
Banerjee, Arnob
Magen, Hila
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Polepally, A.
Badillo, J.
Rinas, M.
Ahsan, A.
Bueno, O.
Talati, C.
Menon, R.
Engelhardt, B.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
[37] Updated Results of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study
Jakubowiak, Andrzej J.
Anguille, Sebastien
Karlin, Lionel
Chari, Ajai
Schinke, Carolina
Rasche, Leo
San-Miguel, Jesus
Campagna, Michela
Hilder, Brandi W.
Masterson, Tara J.
Qin, Xiang
Renaud, Thomas
Tolbert, Jaszianne
Vishwamitra, Deeksha
Skerget, Sheri
Moreau, Philippe
BLOOD, 2023, 142
[38] First results from the RedirecTT-1 study with teclistamab (tec) plus talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Magen, Hila
Morillo, Daniel
Gatt, Moshe
Sebag, Michael
Kim, Kihyun
Min, Chang-Ki
Oriol, Albert
Ocio, Enrique
Yoon, Sung-Soo
Mateos, Maria-Victoria
Chu, Michael
Rodriguez-Otero, Paula
Avivi, Irit
Guo, Yue
Krevvata, Maria
Peterson, Michelle
Beelen, Melissa
Vanak, Jill
Banerjee, Arnob
Cohen, Yael
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S50
[39] Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
Yang, Xu
Wang, Feiqing
Yuan, Xiaoshuang
Yang, Bo
Chen, Juan
Cheng, Jinyang
Liu, Guangyang
Tang, Dongxin
Xu, Xiao
Wang, Sanbin
He, Zhixu
Liu, Yang
Li, Yanju
FRONTIERS IN IMMUNOLOGY, 2024, 15
[40] Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Merz, Maximilian
Dima, Danai
Hashmi, Hamza
Ahmed, Nausheen
Stoelzel, Friedrich
Holderried, Tobias A. W.
Fenk, Roland
Mueller, Fabian
Tovar, Natalia
Oliver-Caldes, Aina
Rathje, Kristin
Davis, James A.
Fandrei, David
Vucinic, Vladan
Kharboutli, Soraya
Baermann, Ben-Niklas
Ayuk, Francis
Platzbecker, Uwe
Albici, Anca-Maria
Schub, Nathalie
Schmitz, Friederike
Shune, Leyla
Khouri, Jack
Anwer, Faiz
Raza, Shahzad
Mcguirk, Joseph
Mahmoudjafari, Zahra
Green, Kimberly
Khandanpour, Cyrus
Teichert, Marcel
Jeker, Barbara
Hoffmann, Michele
Kroeger, Nicolaus
von Tresckow, Bastian
de Larrea, Carlos Fernandez
Pabst, Thomas
Abdallah, Al-Ola
Gagelmann, Nico
BLOOD CANCER JOURNAL, 2024, 14 (01):

← 1 2 3 4 5 →